Ultimovacs ASA - Asset Resilience Ratio

Latest as of March 2024: 0.31%

Ultimovacs ASA (ULTI) has an Asset Resilience Ratio of 0.31% as of March 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read ULTI total liabilities for a breakdown of total debt and financial obligations.

Liquid Assets

Nkr961.00K

≈ $101.12K USD Cash + Short-term Investments

Total Assets

Nkr307.62 Million

≈ $32.37 Million USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2016–2022)

This chart shows how Ultimovacs ASA's Asset Resilience Ratio has changed over time. See Ultimovacs ASA defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.

Liquid Assets Composition Over Time

This chart breaks down Ultimovacs ASA's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Ultimovacs ASA balance sheet assets.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	Nkr0.00	0%
Short-term Investments	Nkr961.00K	0.31%
Total Liquid Assets	Nkr961.00K	0.31%

Asset Resilience Insights

Limited Liquidity: Ultimovacs ASA maintains only 0.31% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

Ultimovacs ASA Industry Peers by Asset Resilience Ratio

Compare Ultimovacs ASA's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
BRITANNIA LIFE SCIENCES F:L020	Biotechnology	63.76%
Revolution Medicines Inc NASDAQ:RVMD	Biotechnology	65.10%
argenx NV ADR NASDAQ:ARGX	Biotechnology	10.93%
Halozyme Therapeutics Inc NASDAQ:HALO	Biotechnology	12.71%
Biomarin Pharmaceutical Inc NASDAQ:BMRN	Biotechnology	0.00%
Tubize-Fin BR:TUB	Biotechnology	0.05%
Abivax SA PA:ABVX	Biotechnology	2.34%
ABCELLERA BIOLOGICS F:8QQ	Biotechnology	29.87%

Annual Asset Resilience Ratio for Ultimovacs ASA (2016–2022)

The table below shows the annual Asset Resilience Ratio data for Ultimovacs ASA.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2022-12-31	1.34%	Nkr6.81 Million ≈ $716.40K	Nkr509.67 Million ≈ $53.63 Million	+0.24pp
2021-12-31	1.09%	Nkr7.17 Million ≈ $754.39K	Nkr655.54 Million ≈ $68.98 Million	-0.56pp
2020-12-31	1.66%	Nkr8.77 Million ≈ $922.86K	Nkr529.72 Million ≈ $55.74 Million	+0.17pp
2019-12-31	1.49%	Nkr7.12 Million ≈ $748.70K	Nkr478.04 Million ≈ $50.30 Million	-1.78pp
2018-12-31	3.27%	Nkr6.21 Million ≈ $653.37K	Nkr189.86 Million ≈ $19.98 Million	+0.45pp
2017-12-31	2.82%	Nkr5.04 Million ≈ $530.04K	Nkr178.82 Million ≈ $18.82 Million	-3.54pp
2016-12-31	6.36%	Nkr5.25 Million ≈ $552.98K	Nkr82.63 Million ≈ $8.69 Million	--

pp = percentage points

About Ultimovacs ASA

OL:ULTI Norway Biotechnology

Market Cap

$52.14 Million

Nkr495.45 Million NOK

Market Cap Rank

#21780 Global

#194 in Norway

Share Price

Nkr14.40

Change (1 day)

+0.00%

52-Week Range

Nkr14.40 - Nkr14.40

All Time High

Nkr162.00